Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment
Crossref DOI link: https://doi.org/10.1007/s00280-023-04587-8
Published Online: 2023-09-16
Published Print: 2024-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Oya, Mototsugu
Kaneko, Shuichi
Imai, Tsuneo
Tsujino, Toshiaki
Sunaya, Toshiyuki
Okayama, Yutaka http://orcid.org/0000-0001-5242-1710
Text and Data Mining valid from 2023-09-16
Version of Record valid from 2023-09-16
Article History
First Online: 16 September 2023